Koch E, Heppt M, Berking C (2024)
Publication Type: Journal article
Publication year: 2024
DOI: 10.1007/s40257-024-00872-1
Uveal melanoma (UM) is genetically a distinct tumor compared to cutaneous melanoma (CM), and due to its low mutational burden, it is far less perceptible to the immune system. Thus, treatments that have revolutionized the treatment of CM remain widely inefficient in metastatic UM or only demonstrate effectiveness in a small subpopulation of patients. To this end, the therapeutic benefit of immune checkpoint blockade is very limited and may come at the expense of severe immune-related adverse events that could potentially affect all organ systems. Notably, tebentafusp, an entirely novel class of anti-cancer drugs, has received official authorization for the treatment of metastatic UM. It is the first agent that demonstrated a survival advantage in a randomized controlled trial of metastatic UM patients. Despite the survival benefit and approval, the restriction of tebentafusp to HLA-A*02:01-positive patients and the low objective response rate indicate the persistent need for additional therapies. Thus, liver-directed therapies are commonly used for tumor control of hepatic metastases and represent a central pillar of the daily management of liver-dominant disease. Further, promising data from targeted therapies independent of MEK-inhibitors, such as the combination of darovasertib and crizotinib, raise hope for additional options in metastatic UM in the future. This narrative review provides a timely and comprehensive overview of the current treatment landscape for metastatic UM.
APA:
Koch, E., Heppt, M., & Berking, C. (2024). The Current State of Systemic Therapy of Metastatic Uveal Melanoma. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-024-00872-1
MLA:
Koch, Elias, Markus Heppt, and Carola Berking. "The Current State of Systemic Therapy of Metastatic Uveal Melanoma." American Journal of Clinical Dermatology (2024).
BibTeX: Download